Endo Withdraws Opana Painkiller From Market at FDA’s Request Post author:Sam Post published:July 6, 2017 Post category:Drug Industry Daily Endo will withdraw Opana ER from the market, following an FDA request in June. Source: Drug Industry Daily You Might Also Like GAO Recommends That FDA Overhaul Strategic Workforce Planning January 18, 2022 FDA Invites Meeting Requests for Pilot Program to Spur Clinical Trial Innovation August 29, 2018 U.S. Cancer Drug Spending Nearly Doubled From 2017: IQVIA May 24, 2018